Prime Medicine, Inc. (PRME)
| Market Cap | 655.19M +310.6% |
| Revenue (ttm) | 4.63M +55.3% |
| Net Income | -201.14M |
| EPS | -1.35 |
| Shares Out | 177.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,593,856 |
| Open | 3.820 |
| Previous Close | 3.840 |
| Day's Range | 3.660 - 3.870 |
| 52-Week Range | 1.110 - 6.940 |
| Beta | 2.67 |
| Analysts | Buy |
| Price Target | 7.56 (+104.32%) |
| Earnings Date | May 8, 2026 |
About PRME
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular in... [Read more]
Financial Performance
In 2025, Prime Medicine's revenue was $4.63 million, an increase of 55.28% compared to the previous year's $2.98 million. Losses were -$201.14 million, 2.69% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for PRME stock is "Buy." The 12-month stock price target is $7.56, which is an increase of 104.32% from the latest price.
News
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therap...
Prime Medicine Transcript: The Citizens Life Sciences Conference 2026
Two in vivo programs are advancing to the clinic with data expected in 2027, while a revived ex vivo program benefits from regulatory flexibility and reduced costs. Prime Editing's DNA-level correction offers broad applicability, strong safety, and competitive advantages in genetic diseases.
Prime Medicine Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing its first in vivo liver-directed clinical programs for Wilson disease and alpha-1 antitrypsin deficiency, with regulatory filings expected soon and initial clinical data anticipated in 2027. Strategic partnerships, a strong IP position, and a cash runway into 2027 support a focused pipeline and ongoing business development.
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for PM3...
Prime Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine Transcript: 44th Annual J.P. Morgan Healthcare Conference
Prime Editing technology enables precise, safe genome editing with broad disease potential and strong IP protection. Lead programs in Wilson disease and alpha-1 antitrypsin deficiency are advancing toward clinical trials, supported by a $227M cash position and strategic partnerships.
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine Transcript: Evercore ISI 8th Annual HealthCONx Conference
Prime editing is positioned as a safer, more versatile gene editing technology, with a strategic focus on high-value programs like Wilson disease and alpha-1 antitrypsin deficiency. Lead programs are advancing toward clinical trials, with data expected in 2027.
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine Transcript: Jefferies London Healthcare Conference 2025
Prime Editing is positioned as a highly versatile and safe gene editing platform, advancing programs in Wilson's disease, AATD, and cystic fibrosis with promising preclinical data and differentiated delivery technology. Key regulatory filings and clinical milestones are expected over the next year.
Prime Medicine Transcript: KOL Event
The event detailed a strategy to address Wilson disease using prime editing, highlighting strong preclinical efficacy, a large addressable market, and a modular platform for rapid expansion. IND/CTA filing is planned for 2026, with initial human data expected in 2027.
Prime Medicine to Present at Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
-- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as dev...
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
-- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as dev...
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine Transcript: Chardan’s 9th Annual Genetic Medicines Conference
Panelists at a leading genome editing conference discussed the coexistence of editing technologies, the importance of delivery optimization, and the shift toward commercially viable, one-time therapies. Advances in LNP and AAV delivery, platform synergies, and a focus on cost and access are shaping the next wave of clinical programs.
Prime Medicine Transcript: H. C. Wainwright Genetic Medicines Virtual Conference
Prime Editing technology enables precise, safe, and versatile gene editing, with a current focus on liver diseases such as Wilson's and alpha-1 antitrypsin deficiency. Key programs are set to enter the clinic in 2025, with data expected in 2027, supported by a strong cash position and strategic collaborations.
Prime Medicine Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Strategic focus is on high-potential liver and cystic fibrosis programs, leveraging Prime Editing’s precision and safety advantages. INDs for Wilson’s disease and Alpha-1 antitrypsin deficiency are targeted for 2026, with phase 1 data expected in 2027. Financial runway extends into 2027, supported by cost reductions and partnerships.
Prime Medicine Transcript: Citi's Biopharma Back to School Conference
Leadership transition led to a focused pipeline of three core programs and a major BMS collaboration. INDs for Wilson's and AATD are expected in 2025, with clinical data in 2027. Strong preclinical data, a robust financial position, and ongoing BD efforts support long-term growth.
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates
-- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interact...
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine Announces Pricing of Public Offering
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...